Alterity Therapeutics Limited
NASDAQ:ATHEBiotechnology
+$0.53 today
- Market cap
- $52.77M
- Beta
- -0.03
- P/E (TTM)
- -9.9
- EPS (TTM)
- -$0.07
Volume 0.02M
Average 0.05M
ATHE Deferred Revenue (Non-current)
Payments received for goods or services the company will deliver after more than one year.
Alterity Therapeutics LimitedNASDAQ: ATHE
Deferred Revenue (Non-current) · Q2 FY2026 · quarter ended Dec 2025
Deferred revenue (non-current) remains negative
Q2 FY2026 deferred revenue (non-current) was A$0, compared with A$0 a year earlier.
Context
- Deferred revenue (non-current) amounted to 0.0% of total assets at the end of Q2 FY2026, unchanged from a year earlier.
- Deferred revenue (non-current) increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Deferred Revenue (Non-current) history
AUD · from the balance sheet
- Latest · FY2025
- 0 AUD
- Year-over-year change
- —
| Period | Period end | Deferred Revenue (Non-current) | YoY change |
|---|---|---|---|
| FY2025 | 2025-06-30 | 0 | — |
| FY2024 | 2024-06-30 | 0 | — |
| FY2023 | 2023-06-30 | 0 | — |
| FY2022 | 2022-06-30 | 0 | — |
| FY2021 | 2021-06-30 | 0 | — |
Deferred Revenue (Non-current) vs competitors
How ATHE compares with its peers on the latest reported figures
- Peers report in different currencies, so deferred revenue (non-current) is compared through growth and share of total assets rather than absolute size.
- Deferred revenue (non-current) amounts to 0.0% of total assets for ATHE, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Dec 2025 | A$0 AUD | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding ATHE) | — | — | — | 0.0% | |
Competitors are the stored peer set for ATHE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Jun 2021 | FY2022 Jun 2022 | FY2023 Jun 2023 | FY2024 Jun 2024 | FY2025 Jun 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 28.12M | 34.81M | 15.77M | 12.64M | 33.16M |
| Short-term Investments | 0 | 0 | 0 | 0 | 7.5M |
| Net Receivables | 4.13M | 4.67M | 8.65M | 4.04M | 3.94M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 160.67K | 66.19K | 56.6K | 40.67K | 41.82K |
| Total Current Assets | 33.49M | 41.14M | 27.05M | 19.04M | 45.87M |
| Property, Plant & Equipment (Net) | 96.81K | 218.52K | 268.86K | 186.88K | 155.17K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Assets | 96.81K | 218.52K | 268.86K | 186.88K | 155.17K |
| Total Assets | 33.59M | 41.36M | 27.32M | 19.22M | 46.03M |
| Account Payables | 1.45M | 2.64M | 1.72M | 581.14K | 538.28K |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 26.92K | 27.93K | 15.99K | 16.28K |
| Deferred Revenue | 0 | (57.63K) | (107.18K) | 0 | 0 |
| Other Current Liabilities | 33.85K | 2.5M | 169.02K | 4.12M | 876.05K |
| Total Current Liabilities | 3.07M | 5.82M | 4.38M | 5.37M | 3.53M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 9.77K | 13.75K | 19.5K | 0 | 0 |
| Total Non-current Liabilities | 47.67K | 73.61K | 122.71K | 51.91K | 88.55K |
| Total Liabilities | 3.12M | 5.89M | 4.5M | 5.43M | 3.62M |
| Common Stock | 197.45M | 213.79M | 213.97M | 223.15M | 262.95M |
| Retained Earnings | (169.73M) | (181.88M) | (195.13M) | (214.16M) | (225.89M) |
| Accumulated OCI | 2.75M | 3.57M | 3.97M | 4.81M | 5.34M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 30.47M | 35.47M | 22.81M | 13.8M | 42.4M |
| Total Debt | 65.65K | 117.49K | 210.38K | 159.05K | 155.46K |
| Net Debt | (28.05M) | (34.69M) | (15.56M) | (12.48M) | (33M) |
Alterity Therapeutics Limited
NASDAQ:ATHE
Intrinsic Alpha fair value
Locked
Current Price
$3.12
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.